Press release: Turnover ceiling for innovative drugs is axed
BIO Deutschland welcomes changes to the draft bill
On 9 March, the German Bundestag passed the Act to Strengthen Pharmaceutical Supply in the Statutory Health Insurance System (AM-VSG) with votes from the ruling CDU and SPD parties. The proposed turnover ceiling for innovative medicinal products, which would have been set at €250 million for the first year after approval, was removed from the bill entirely. The biotechnology sector association, BIO Deutschland, which had strongly criticised the planned introduction of a turnover ceiling, expressly welcomes the change to the new law made by the health committee. In a statement last year, the association had called for a removal of the turnover ceiling, because such a provision would have been a very negative signal for the development of highly innovative medicinal products.